NEAR INFRARED IMAGING OF MMP-2/MM-9 WITH A HIGHLY SPECIFIC OPTICAL PROBE
NEAR INFRARED IMAGING OF MMP-2/MM-9 WITH A HIGHLY SPECIFIC OPTICAL PROBE
批准号:
7909373
负责人:
Wilson Barry Edwards
金额:
$4.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2010-07-31
关键词:
AccountingAdjuvant TherapyAmidesAnimal ModelBasement membraneBiological AssayBreastCellsCervix UteriCircular Dichroism SpectroscopyClinical TrialsCollagenCollagen Type VDiagnosisDiagnostic ImagingDyesEnzymesEquipmentExtracellular Matrix DegradationFluorescenceFluorescence MicroscopyGelatinasesGenus ColaGoalsHomoHumanHydrolysisImageIndividualInterventionLifeLightLightingLungMalignant NeoplasmsMasticationMatrix MetalloproteinasesMeasuresMediatingMethodsMolecularMolecular Sieve ChromatographyMonitorMusNeoplasm MetastasisNormal tissue morphologyOpticsPatientsPeptide HydrolasesPeptidesPharmaceutical PreparationsPharmacologic SubstancePhasePrimary NeoplasmProstateProtease InhibitorProteinsRelative (related person)ResearchResistanceRoleSamplingScanningSerumSkin NeoplasmsSolidSourceSpecificitySpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStructureTestingTherapeutic InterventionThyroid GlandToxic effectTreatment EfficacyXenograft procedureangiogenesisbasecancer diagnosiscytotoxicitydesignin vivomalignant breast neoplasmmelanomaminimally invasivemouse modeloptical imagingprognosticprotective effectproteinase Inpublic health relevanceresearch studysubcutaneoustumortumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Matrix metallo-proteinases (MMPs) are often present in high levels in cancer such as tumors of the skin, breast, thyroid, cervix, lung, colon and prostate, but absent in normal tissues. MMPs are enzymes that are capable of chewing through the protein barriers that hold the primary tumor in its place. Once these barriers are degraded, the tumor can spread, or metastasize, throughout the body. We are designing a probe, to administer to the patient, that will remain invisible until it is degraded by the MMPs. After it is chewed in half, the probe will light up. We will capture and measure the light with optical imaging equipment and know that the tumor contains high levels of MMPs. The major pharmaceutical companies are currently developing drugs that will inhibit the action of the MMPs, thus slowing metastasis or stopping it altogether. If we are successful, the probe could be used to decide whether to initiate MMP inhibitor therapy and to monitor the therapy once it has begun. It could also be used to identify which tumors are likely to metastasize. The equipment used for optical imaging is relatively inexpensive and uncomplicated. A patient would likely be scanned at the office of their doctor. To test whether the probes will be effective in lighting up tumors we will perform the following Aims. Aim 1: The probes will be prepared from commercially available starting materials, separated from the starting materials if necessary, and tested for their purity Aim 2: Before testing in animal models, the probes will be tested in a variety of ways to show that they will indeed be chewed in half by MMPs and release the quantity of light needed to visualize a tumor growing in a living being. The stability and toxicity of the probes will be tested as well. Aim 3: Finally the probes will be tested in an animal model to see whether the tumors light up to an extent that the light is significant enough to be quantified. A variety of experiments (controls) will be used to make sure that the light observed is indeed due to MMP action and not from another source. PUBLIC HEALTH RELEVANCE The goal of this research is to develop pharmaceuticals that are optically invisible until they encounter a tumor and light up in its presence. Ultimately, these agents will allow for rapid and non-invasive or minimally invasive diagnosis of cancer.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Engineered antibody fragments for PET imaging of immunotherapeutic targets in gliomas
-
批准号:10459345
-
项目类别:
-
资助金额:$52.89万
-
财政年份:2020
-
负责人:Wilson Barry Edwards
-
依托单位:
Engineered antibody fragments for PET imaging of immunotherapeutic targets in gliomas
-
批准号:10217058
-
项目类别:
-
资助金额:$55.0万
-
财政年份:2020
-
负责人:Wilson Barry Edwards
-
依托单位:
Engineered Antibodies as PET Probes for Monitoring Immunotherapy Responses
-
批准号:10197929
-
项目类别:
-
资助金额:$23.48万
-
财政年份:2020
-
负责人:Wilson Barry Edwards
-
依托单位:
Engineered antibody fragments for PET imaging of immunotherapeutic targets in gliomas
-
批准号:10646321
-
项目类别:
-
资助金额:$52.89万
-
财政年份:2020
-
负责人:Wilson Barry Edwards
-
依托单位:
CD11b Antibody Fragments as PET Imaging Probes for Glioma-Associated Myeloid Cells
-
批准号:9751856
-
项目类别:
-
资助金额:$23.42万
-
财政年份:2018
-
负责人:Wilson Barry Edwards
-
依托单位:
Identification of receptors for transcytotic delivery of therapeutic agents crossing the BBB
-
批准号:9265140
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2016
-
负责人:Wilson Barry Edwards
-
依托单位:
SELECTIVELY IMAGING CANCER STEM CELLS
-
批准号:8338791
-
项目类别:
-
资助金额:$19.77万
-
财政年份:2011
-
负责人:Wilson Barry Edwards
-
依托单位:
SELECTIVELY IMAGING CANCER STEM CELLS
-
批准号:8095997
-
项目类别:
-
资助金额:$16.48万
-
财政年份:2011
-
负责人:Wilson Barry Edwards
-
依托单位:
NEAR INFRARED IMAGING OF MMP-2/MM-9 WITH A HIGHLY SPECIFIC OPTICAL PROBE
-
批准号:7616539
-
项目类别:
-
资助金额:$17.1万
-
财政年份:2008
-
负责人:Wilson Barry Edwards
-
依托单位:
NEAR INFRARED IMAGING OF MMP-2/MM-9 WITH A HIGHLY SPECIFIC OPTICAL PROBE
-
批准号:7531906
-
项目类别:
-
资助金额:$20.52万
-
财政年份:2008
-
负责人:Wilson Barry Edwards
-
依托单位:
海外基金